Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

BACKGROUND: The immunomodulation of the antitumor response driven by immunocheckpoint inhibitors (ICIs) such as PD-L1 (Programmed Death Ligand-1) monoclonal antibody (α-PD-L1) have shown relevant clinical outcomes in a subset of patients. This fact has led to the search for rational combinations wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Merino, María, Lozano, Teresa, Casares, Noelia, Lana, Hugo, Troconiz, Iñaki F., ten Hagen, Timo L. M., Kochan, Grazyna, Berraondo, Pedro, Zalba, Sara, Garrido, María J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042980/
https://www.ncbi.nlm.nih.gov/pubmed/33849551
http://dx.doi.org/10.1186/s12951-021-00846-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042980/
https://www.ncbi.nlm.nih.gov/pubmed/33849551
http://dx.doi.org/10.1186/s12951-021-00846-z

Ejemplares similares